TY - JOUR
T1 - Frontal systems deficits in stimulant-dependent patients
T2 - Evidence of pre-illness dysfunction and relationship to treatment response
AU - Winhusen, Theresa M.
AU - Somoza, Eugene C.
AU - Lewis, Daniel F.
AU - Kropp, Frankie B.
AU - Horigian, Viviana Elizabeth
AU - Adinoff, Bryon
N1 - Funding Information:
This study was supported by the following grants from the National Institute on Drug Abuse (NIDA) Clinical Trials Network : U10-DA013036 to Oregon Health and Science University (Dr. McCarty); U10-DA013732 to the University of Cincinnati (Drs. Somoza/Winhusen); U10-DA013720 to the University of Miami School of Medicine (Dr. Szapocznik); U10-DA020024 to the University of Texas Southwestern Medical Center (Drs. Adinoff/Trivedi); and U10-DA013714 to the University of Washington (Dr. Donovan). The data and safety monitoring board (DSMB) of the Center Clinical Trials Network (CCTN) of the National Institute on Drug Abuse (NIDA) provided guidance and final approval for the study design. The director and deputy director of the CCTN, the DSMB of the CCTN, and a quality assurance subcontractor to the CCTN monitored study conduct, data collection, and data management. A subcontractor to the CCTN was responsible for data management. The publications committee of the Clinical Trials Network (CTN) gave final approval of the analysis and interpretation of the data and approved the manuscript.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Background: Frontal systems dysfunction is present in stimulant-dependent patients. However, it is unclear whether this dysfunction is a pre-morbid risk factor or stimulant-induced, is severe enough to be clinically relevant, and if it is relevant to treatment response. These questions were addressed using the Frontal Systems Behavior Scale (FrSBe), a reliable and valid self-report assessment of three neurobehavioral domains associated with frontal systems functioning (Apathy, Disinhibition, and Executive Dysfunction, summed for a Total), that assesses both pre- and post-morbid functioning, and has a specific cutoff for defining clinically significant abnormalities. Method: Six sites evaluating 12-step facilitation for stimulant abusers obtained the FrSBe from 180 methamphetamine- and/or cocaine-dependent participants. Dichotomous treatment response measures included self-reported stimulant use, stimulant urine drug screens, and treatment completion. Results: A substantial percentage of participants retrospectively reported clinically significant neurobehavioral abnormalities prior to lifetime stimulant abuse initiation (e.g., 67.5% on FrSBe-Total) with a significant increase in the proportion reporting such abnormalities for current functioning (86% on FrSBe-Total; p< 0.0001). Treatment response was significantly worse for participants with, relative to those without, clinically significant Disinhibition as measured by treatment non-completion (31.6% vs. 15.6%, OR = 2.51) and self-reported stimulant use during treatment (40.5% vs. 16.7%, OR = 3.40). Conclusion: These findings suggest that frontal systems dysfunction is present prior to stimulant-abuse onset and worsens with stimulant use. Disinhibition may be a prime target for intervention in stimulant-dependent individuals.
AB - Background: Frontal systems dysfunction is present in stimulant-dependent patients. However, it is unclear whether this dysfunction is a pre-morbid risk factor or stimulant-induced, is severe enough to be clinically relevant, and if it is relevant to treatment response. These questions were addressed using the Frontal Systems Behavior Scale (FrSBe), a reliable and valid self-report assessment of three neurobehavioral domains associated with frontal systems functioning (Apathy, Disinhibition, and Executive Dysfunction, summed for a Total), that assesses both pre- and post-morbid functioning, and has a specific cutoff for defining clinically significant abnormalities. Method: Six sites evaluating 12-step facilitation for stimulant abusers obtained the FrSBe from 180 methamphetamine- and/or cocaine-dependent participants. Dichotomous treatment response measures included self-reported stimulant use, stimulant urine drug screens, and treatment completion. Results: A substantial percentage of participants retrospectively reported clinically significant neurobehavioral abnormalities prior to lifetime stimulant abuse initiation (e.g., 67.5% on FrSBe-Total) with a significant increase in the proportion reporting such abnormalities for current functioning (86% on FrSBe-Total; p< 0.0001). Treatment response was significantly worse for participants with, relative to those without, clinically significant Disinhibition as measured by treatment non-completion (31.6% vs. 15.6%, OR = 2.51) and self-reported stimulant use during treatment (40.5% vs. 16.7%, OR = 3.40). Conclusion: These findings suggest that frontal systems dysfunction is present prior to stimulant-abuse onset and worsens with stimulant use. Disinhibition may be a prime target for intervention in stimulant-dependent individuals.
KW - Cocaine
KW - FrSBe
KW - Methamphetamine
KW - Prefrontal cortex dysfunction
KW - Stimulant
UR - http://www.scopus.com/inward/record.url?scp=84870858864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870858864&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2012.06.017
DO - 10.1016/j.drugalcdep.2012.06.017
M3 - Article
C2 - 22771145
AN - SCOPUS:84870858864
SN - 0376-8716
VL - 127
SP - 94
EP - 100
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
IS - 1-3
ER -